Galaxy Life Sciences, LLC (Galaxy) has retained MidPoint Engineering and Consulting (MidPoint) to start site design and planning services for its second new biomanufacturing facility at The Reactory in Worcester, MA. MidPoint will commence site design and civil engineering to accommodate the new facility along with potential expansion area. This 21-acre parcel known as the A lot is the largest parcel at the 46-acre master-planned biomanufacturing campus developed by the Worcester Business Development Corporation (WBDC) at the site of the former Worcester State Hospital. With MEPA permits already in place, the project will be put on a fast track to design and build as soon as possible to accommodate tenant requirements.
Galaxy has already started construction on the 6-acre D lot with foundations being installed now and steel planned for October. MidPoint has also provided an expansion plan for this parcel that extends the building onto the B lot to accommodate a much larger footprint if required. The only other parcel within The Reactory is being developed by WuXi Biologics for a 200,000 SF clinical and commercial manufacturing facility which is also under construction.
Just 2 months ago, the City of Worcester accepted a name change for Hospital Drive therefore establishing Reactory Drive. WBDC recently completed a new driveway entrance to the 550,000 SF AbbVie Bioresearch Center as part of the overall Reactory project. The AbbVie property is adjacent to the Galaxy B/D building already under construction.
About Galaxy Development & Galaxy Life Sciences
Galaxy Development, LLC of Webster, Mass., specializes in the acquisition, design, construction and leasing of retail, life sciences, medical, residential and industrial properties throughout New England with properties located in Massachusetts, Connecticut and New York. Its life sciences team provides biotechnology and pharmaceutical companies with dynamic, multi-modal facilities accommodating the research, development, and manufacturing of multiple types of process, including biologics, cell therapies, and gene therapies. For more information, please visit GalaxyLifeSciences.net.